OncoSec Medical (ONCS) Falls 2%: What’s Next?

During the last week, OncoSec Medical (ONCS) stock has been decreasing with continuous speed, and it was closed at $2.18. Furthermore, the price indicators have been showing the negative change in volume on the stock chart altogether with the fall from $2.46 to $2.83, which respectively represents a 2% drop. Moreover, OncoSec Medical, last month, announced it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoSec’s TAVO with Merck’s KEYTRUDA in a Phase 3 study. For today, the total market capitalization of the company is 80.722M.

Furthermore, the company has recently announced the establishment of a Leadership Committee consisting of three board members, Margaret Dalesandro, Ph.D., Herbert Kim Lyerly, M.D., and Yuhang Zhao, Ph.D., MBA, to lead all development efforts. Additionally, Director Margaret Dalesandro acquired a total of 20000 shares at an average price of $1.89. To acquire these shares costs $37,800.00.

Michael Rowels

Weekend Contributor.Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.